Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• Baldwin LA, Huang B, Miller RW, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012;120(3). doi:10.1097/AOG.0b013e318264f794
   PubMed Web of Science ®Google Scholar
• Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer. 2009;115(6):1234–1244. doi:10.1002/cncr.2414919189349
   PubMed Web of Science ®Google Scholar
• Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol. 2006;100(1):33–37. doi:10.1016/j.ygyno.2005.07.12316153692
   PubMed Web of Science ®Google Scholar
• Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357(9251):176–182. doi:10.1016/S0140-6736(00)03590-X11213094
   PubMed Web of Science ®Google Scholar
• Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1990;75(2):263–273. Available from: http://europepmc.org/abstract/MED/2300355. Accessed July 15, 2019.2300355
   PubMed Web of Science ®Google Scholar
• Kossaï M, Leary A, Scoazec J-Y, Genestie C. Ovarian cancer: a heterogeneous disease. Pathobiology. 2018;85(1–2):41–49. doi:10.1159/00047900629020678
   PubMed Web of Science ®Google Scholar
• van der Wijst MGP, Brown R, Rots MG. Nrf2, the master redox switch: the Achilles’ heel of ovarian cancer? Biochim Biophys Acta. 2014;1846(2):494–509. doi:10.1016/j.bbcan.2014.09.00425270772
   PubMed Web of Science ®Google Scholar
• Namani A, Matiur Rahaman M, Chen M, Tang X. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer. BMC Cancer. 2018;18(1):46. doi:10.1186/s12885-017-3907-z29306329
   PubMedGoogle Scholar
• Boustani MR, Khoshnood RJ, Nikpasand F, et al. Overexpression of ubiquitin-specific protease 2a (USP2a) and nuclear factor erythroid 2-related factor 2 (Nrf2) in human gliomas. J Neurol Sci. 2016;363:249–252. doi:10.1016/j.jns.2016.03.00327000259
   PubMed Web of Science ®Google Scholar
• Ji L, Wei Y, Jiang T, Wang S. Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival. Int J Clin Exp Pathol. 2014;7(3):1124–1131. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24695690. Accessed July 15, 2019.24695690
   PubMed Web of Science ®Google Scholar
• Jiang T, Chen N, Zhao F, et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010;70(13):5486–5496. doi:10.1158/0008-5472.CAN-10-071320530669
   PubMed Web of Science ®Google Scholar
• Ryoo I, Choi B, Kwak M-K. Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells. Oncotarget;. 2015;6(10). doi:10.18632/oncotarget.v6i10
   Google Scholar
• Czogalla B, Kahaly M, Mayr D, et al. Interaction of ERα and NRF2 impacts survival in ovarian cancer patients. Int J Mol Sci. 2018;20:1. doi:10.3390/ijms20010112
   PubMed Web of Science ®Google Scholar
• Zhang DD. The Nrf2-Keap1-ARE signaling pathway: the regulation and dual function of Nrf2 in cancer. Antioxid Redox Signal. 2010;13(11):1623–1626. doi:10.1089/ars.2010.330120486759
   PubMed Web of Science ®Google Scholar
• Lo R, Matthews J. The aryl hydrocarbon receptor and estrogen receptor alpha differentially modulate nuclear factor erythroid-2-related factor 2 transactivation in MCF-7 breast cancer cells. Toxicol Appl Pharmacol. 2013;270(2):139–148. doi:10.1016/j.taap.2013.03.02923583297
   PubMed Web of Science ®Google Scholar
• Wu N-Y, Huang H-S, Chao TH, et al. Progesterone prevents high-grade serous ovarian cancer by inducing necroptosis of p53-defective fallopian tube epithelial cells. Cell Rep. 2017;18(11):2557–2565. doi:10.1016/j.celrep.2017.02.04928297660
   PubMed Web of Science ®Google Scholar
• Jeon S-Y, Hwang K-A, Choi K-C. Effect of steroid hormones, estrogen and progesterone, on epithelial mesenchymal transition in ovarian cancer development. J Steroid Biochem Mol Biol. 2016;158:1–8. doi:10.1016/j.jsbmb.2016.02.00526873134
   PubMed Web of Science ®Google Scholar
• Nagendra PB, Goad J, Nielsen S, et al. Ovarian hormones through Wnt signalling regulate the growth of human and mouse ovarian cancer initiating lesions. Oncotarget. 2016;7(40):64836–64853. doi:10.18632/oncotarget.1171127588493
   PubMedGoogle Scholar
• Lurie G, Wilkens LR, Thompson PJ, et al. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology. 2008;19(2). doi:10.1097/EDE.0b013e31816334c5
   PubMed Web of Science ®Google Scholar
• Akahira J, Inoue T, Suzuki T, et al. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer. 2000;83(11):1488–1494. doi:10.1054/bjoc.2000.146311076658
   PubMed Web of Science ®Google Scholar
• Akahira J-I, Suzuki T, Ito K, et al. Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. Jpn J Cancer Res. 2002;93(7):807–815. doi:10.1111/j.1349-7006.2002.tb01323.x12149147
   PubMedGoogle Scholar
• Lenhard M, Tereza L, Heublein S, et al. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer. 2012;12:553. doi:10.1186/1471-2407-12-55323176303
   PubMed Web of Science ®Google Scholar
• Luo H, Li S, Zhao M, Sheng B, Zhu H, Zhu X. Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis. Oncotarget. 2017;8(22):36845–36856. doi:10.18632/oncotarget.1598228415663
   PubMedGoogle Scholar
• Sinn BV, Darb-Esfahani S, Wirtz RM, et al. Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue. Histopathology. 2011;59(5):918–927. doi:10.1111/j.1365-2559.2011.04028.x22092403
   PubMed Web of Science ®Google Scholar
• Sieh W, Köbel M, Longacre TA, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013;14(9):853–862. doi:10.1016/S1470-2045(13)70253-523845225
   PubMed Web of Science ®Google Scholar
• Diep CH, Daniel AR, Mauro LJ, Knutson TP, Lange CA. Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol. 2015;54(2):R31–R53. doi:10.1530/JME-14-025225587053
   PubMed Web of Science ®Google Scholar
• Scholz C, Heublein S, Lenhard M, Friese K, Mayr D, Jeschke U. Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients. BMC Res Notes. 2012;5:551. doi:10.1186/1756-0500-5-55123036050
   PubMedGoogle Scholar
• Nakas CT, Alonzo TA, Yiannoutsos CT. Accuracy and cut-off point selection in three-class classification problems using a generalization of the Youden index. Stat Med. 2010;29(28):2946–2955. doi:10.1002/sim.404420809485
   PubMed Web of Science ®Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–35. doi:10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-315405679
   PubMed Web of Science ®Google Scholar
• Perkins NJ, Schisterman EF. The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol. 2006;163(7):670–675. doi:10.1093/aje/kwj06316410346
   PubMed Web of Science ®Google Scholar
• Fluss R, Faraggi D, Reiser B. Estimation of the youden index and its associated cutoff point. Biometrical J. 2005;47(4):458–472. doi:10.1002/bimj.200410135
   PubMed Web of Science ®Google Scholar
• Villeneuve NF, Lau A, Zhang DD. Regulation of the Nrf2–keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal. 2010;13(11):1699–1712. doi:10.1089/ars.2010.321120486766
   PubMed Web of Science ®Google Scholar
• Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW. When NRF2 talks, who’s listening? Antioxid Redox Signal. 2010;13(11):1649–1663. doi:10.1089/ars.2010.321620367496
   PubMed Web of Science ®Google Scholar
• Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT. Cancer chemoprevention mechanisms mediated through the Keap1–nrf2 pathway. Antioxid Redox Signal. 2010;13(11):1713–1748. doi:10.1089/ars.2010.322120446772
   PubMed Web of Science ®Google Scholar
• Menegon S, Columbano A, Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med. 2016;22(7):578–593. doi:10.1016/j.molmed.2016.05.00227263465
   PubMed Web of Science ®Google Scholar
• Taguchi K, Yamamoto M. The KEAP1-NRF2 system in cancer. Front Oncol. 2017;7:85. doi:10.3389/fonc.2017.0008528523248
   PubMed Web of Science ®Google Scholar
• Cho H, Kim K, Kim Y-B, Kim H, No JH. Expression patterns of Nrf2 and Keap1 in ovarian cancer cells and their prognostic role in disease recurrence and patient survival. Int J Gynecol Cancer. 2017;27(3). doi:10.1097/IGC.0000000000000908
   Web of Science ®Google Scholar
• Modugno F, Laskey R, Smith AL, Andersen CL, Haluska P, Oesterreich S. Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer. 2012;19(6):R255–R279. doi:10.1530/ERC-12-017523045324
   PubMed Web of Science ®Google Scholar
• Chuffa LGDA, Lupi-Júnior LA, Costa AB, Amorim JPDA, Seiva FRF. The role of sex hormones and steroid receptors on female reproductive cancers. Steroids. 2017;118:93–108. doi:10.1016/j.steroids.2016.12.01128041951
   PubMed Web of Science ®Google Scholar
• Diep C, Charles N, Blake Gilks C, Kalloger S, Argenta P, Lange CA. Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle. 2013;12(9):1433–1449. doi:10.4161/cc.2455023574718
   PubMed Web of Science ®Google Scholar
• Nishizawa M, Nakajima T, Yasuda K, et al. Close kinship of human 20α-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells. 2000;5(2):111–125. doi:10.1046/j.1365-2443.2000.00310.x10672042
   PubMed Web of Science ®Google Scholar
• Rižner TL, Šmuc T, Rupreht R, Šinkovec J, Penning TM. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol. 2006;248(1):126–135. doi:10.1016/j.mce.2005.10.00916338060
   PubMed Web of Science ®Google Scholar
• Ji Q, Aoyama C, Nien Y-D, et al. Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res. 2004;64(20):7610 LP–7617. doi:10.1158/0008-5472.CAN-04-160815492289
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Zhang Z, et al. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway. Oncotarget. 2016;7(9):10363–10372. doi:10.18632/oncotarget.700426824415
   PubMedGoogle Scholar
• Deng HB, Parekh HK, Chow K-C, Simpkins H. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem. 2002;277(17):15035–15043. doi:10.1074/jbc.M11202820011842089
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Hojo A, Yamane Y, Endo S, El-Kabbani O, Hara A. Pathophysiological roles of aldo–keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers. Chem Biol Interact. 2013;202(1):234–242. doi:10.1016/j.cbi.2012.09.024
   Google Scholar
• Murdoch WJ, Van Kirk EA, Isaak DD, Shen Y. Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts. Gynecol Oncol. 2008;110(2):251–255. doi:10.1016/j.ygyno.2008.03.02118495224
   PubMed Web of Science ®Google Scholar
• Yu C, Jiao Y, Xue J, et al. Metformin sensitizes non-small cell lung cancer cells to an epigallocatechin-3-Gallate (EGCG) treatment by suppressing the Nrf2/HO-1 signaling pathway. Int J Biol Sci. 2017;13(12):1560–1569. doi:10.7150/ijbs.1883029230104
   PubMed Web of Science ®Google Scholar
• Zhang J, Jiao K, Liu J, Xia Y. Metformin reverses the resistance mechanism of lung adenocarcinoma cells that knocks down the Nrf2 gene. Oncol Lett. 2018;16(5):6071–6080. doi:10.3892/ol.2018.938230333878
   PubMed Web of Science ®Google Scholar
• Lengyel E, Litchfield LM, Mitra AK, et al. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 2015;212(4):479.e1–479.e10. doi:10.1016/j.ajog.2014.10.026
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhu J, Zhang H, Liu Y, Sun H. Metformin inhibits ovarian cancer growth and migration in vitro and in vivo by enhancing cisplatin cytotoxicity. Am J Transl Res. 2018;10(10):3086–3098. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30416652. Accessed July 15, 2019.30416652
   PubMed Web of Science ®Google Scholar
• Dos Santos Guimarães I, Ladislau-Magescky T, Tessarollo NG, et al. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines. Pharmacol Rep. 2018;70(3):409–417. doi:10.1016/j.pharep.2017.11.00729627688
   PubMed Web of Science ®Google Scholar
• Bishnu A, Sakpal A, Ghosh N, Choudhury P, Chaudhury K, Ray P. Long term treatment of metformin impedes development of chemoresistance by regulating cancer stem cell differentiation through taurine generation in ovarian cancer cells. Int J Biochem Cell Biol. 2019;107:116–127. doi:10.1016/j.biocel.2018.12.01630593952
   PubMed Web of Science ®Google Scholar
• Garrido MP, Vera C, Vega M, Quest AFG, Romero C. Metformin prevents nerve growth factor-dependent proliferative and proangiogenic effects in epithelial ovarian cancer cells and endothelial cells. Ther Adv Med Oncol. 2018;10:1758835918770984. doi:10.1177/175883591877098429774060
   PubMed Web of Science ®Google Scholar
• Tang G, Guo J, Zhu Y, et al. Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation. Int J Oncol. 2018;52(6):1899–1911. doi:10.3892/ijo.2018.434329620187
   PubMed Web of Science ®Google Scholar
• Dang J-H, Jin Z-J, Liu X-J, et al. Metformin in combination with cisplatin inhibits cell viability and induces apoptosis of human ovarian cancer cells by inactivating ERK 1/2. Oncol Lett. 2017;14(6):7557–7564. doi:10.3892/ol.2017.717629344202
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, López-Bonetc E, Cufí S, et al. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat. 2011;14(4–5):212–223. doi:10.1016/j.drup.2011.04.00321600837
   PubMed Web of Science ®Google Scholar
• Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle. 2010;9(22):4461–4468. doi:10.4161/cc.9.22.1404821088486
   PubMed Web of Science ®Google Scholar
• Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9(8):563–575. doi:10.1038/nrc267619629071
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP Kinase–dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269 LP–10273 LP. doi:10.1158/0008-5472.CAN-06-150017062558
   PubMed Web of Science ®Google Scholar
• Lettieri Barbato D, Vegliante R, Desideri E, Ciriolo MR. Managing lipid metabolism in proliferating cells: new perspective for metformin usage in cancer therapy. Biochim Biophys Acta - Rev Cancer. 2014;1845(2):317–324. doi:10.1016/j.bbcan.2014.02.003
   Web of Science ®Google Scholar
• Shi J, Liu B, Wang H, Zhang T, Yang L. Association of metformin use with ovarian cancer incidence and prognosis: a systematic review and meta-analysis. Int J Gynecol Cancer. 2019;29(1):140 LP–146 LP. doi:10.1136/ijgc-2018-00006030640696
   PubMed Web of Science ®Google Scholar
• Wang S-B, Lei K-J, Liu J-P, Jia Y-M. Continuous use of metformin can improve survival in type 2 diabetic patients with ovarian cancer: a retrospective study. Medicine (Baltimore). 2017;96(29):e7605–e7605. doi:10.1097/MD.000000000000760528723808
   PubMed Web of Science ®Google Scholar
• Garcia C, Yao A, Camacho F, Balkrishnan R, Cantrell LA. A SEER-medicare analysis of the impact of metformin on overall survival in ovarian cancer. Gynecol Oncol. 2017;146(2):346–350. doi:10.1016/j.ygyno.2017.05.00628499649
   PubMed Web of Science ®Google Scholar